Secondary hormonal ablation in hormone-independent prostate cancer;Sekundäre hormonablation beim hormonunabhängigen prostatakarzinom

Urologe - Ausgabe A

Volumn 48, Issue 2, 2009, Pages 183-190

  Schilling, D ^a   Gakis, G ^a   Bokeler U ^a   Stenzl, A ^a   Kuczyk, M A ^b   Merseburger, A S ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Hormonal refractivity; Prostate cancer; Secondary hormonal manipulation; Somatostatin analogues

Indexed keywords

ANTIANDROGEN; ELONGATION FACTOR TU; ESTROGEN; GONADORELIN; KETOCONAZOLE; TESTOSTERONE;

ADRENAL GLAND; ANDROGEN THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER INHIBITION; DISEASE COURSE; HORMONE INHIBITION; HUMAN; PROSTATE CANCER; REVIEW; TESTOSTERONE RELEASE; TESTOSTERONE SYNTHESIS; TREATMENT DURATION;

ANDROGEN ANTAGONISTS; ESTROGENS; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 60449086248     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-009-1940-5     Document Type: Review

References (18)

1. Epstein 1996 Am J Surg Pathol 20 286
2. Hedlund 2002 Scand J Urol Nephrol 36 405
3. Heidenreich 2008 Eur Urol 53 68
4. Heidenreich 2005 Urologe A 44 1303
5. Hussain 1994 J Clin Oncol 12 1868
6. Kelly 1993 J Urol 149 607
7. Mitsiades 2001 Expert Opin Investig Drugs 10 1099
8. Oh 2002 Clin Prostate Cancer 1 81
9. Petrylak 2004 N Engl J Med 351 1513
10. Reddy 2006 J Cell Biochem 98 1408
11. Ricke 2007 Differentiation 75 871
12. Schilling 2008 Urologe A 47 1334
13. Small 2004 J Clin Oncol 22 1025
14. Small 1997 J Clin Oncol 15 382
15. Smith 1998 J Clin Oncol 16 1835
16. Tannock 2004 N Engl J Med 351 1502
17. Taylor 1993 J Clin Oncol 11 2167
18. Wilkinson 2004 Eur Urol 45 581